Lantheus控股 LNTH 深 沪
已收盘 02-13 16:00:00 美东时间
69.36
+0.640
+0.93%
华盛通- 最 高70.33
- 今 开68.71
- 成交量 52.85万股
- 最 低 63.37
- 昨 收 68.72
- 总市值 476.05万
- 52周最高 111.29
- 市盈率 静 --
- 换手率 770.08%
- 52周最低 47.27
- 委 比 45.86%
- 总股本 6.86万
- 历史最高 126.8899
- 量 比 0.72
- 振 幅 10.13%
- 历史最低 1.10
- 每 手 1
- 风险率 16.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Lantheus与GE医疗签署在日本开发放射性诊断剂的许可协议
医疗诊断影像制剂研发、制造、销售和分销公司Lantheus Holdings（LNTH）和GE医疗公司（GE HealthCare，GEHC）签署了在日本开发放射性诊断剂PYLARIFY（Piflufolastat F-18）的许可协议。该交易包括监管和制造支持，GE HealthCare将主导商业化工作。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-24 23:31
Lantheus to Present at the 2025 Truist Securities MedTech Conference
Lantheus Holdings, Inc. announced that CEO Brian Markison will present at the 2025 Truist Securities MedTech Conference on June 17 at 8:40 a.m. ET. Live webcast and replay available on the company’s website.
2025-06-10 12:30
Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Lantheus Holdings, Inc. CEO Brian Markison will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 2:40 p.m. ET. A live webcast and replay will be available on the Company’s website at www.lantheus.com.
2025-06-03 12:30
Redburn Atlantic Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $175
Redburn Atlantic analyst Ed Ridley-Day initiates coverage on Lantheus Holdings (NASDAQ:LNTH) with a Buy rating and announces Price Target of $175.
2024-09-03 23:33
Redburn Atlantic Initiates Lantheus Holdings at Buy
06:15 AM EDT, 09/03/2024 (MT Newswires) -- Lantheus Holdings (LNTH) has average rating of buy and price targets ranging from $125 to $165, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, As...
2024-09-03 18:15
Lantheus To Present Additional Clinical Data From Phase 3 Pivotal SPLASH Trial In PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress In Barcelona On Sunday, September 15, 2024
Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of M...
2024-08-20 20:58
